Pokorney, S. D., Chertow, G. M., Al-Khalidi, H., Gallup, D., Dignacco, P., Mussina, K., … Granger, C. B. (2019). Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety. In CIRCULATION (Vol. 140, pp. E988–E989). Philadelphia, PA: LIPPINCOTT WILLIAMS & WILKINS.

Pokorney, Sean D., Glenn M. Chertow, Hussein Al-Khalidi, Dianne Gallup, Pat Dignacco, Kurt Mussina, Nisha Bansal, et al. “Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety.” In CIRCULATION, 140:E988–89. LIPPINCOTT WILLIAMS & WILKINS, 2019.

Pokorney SD, Chertow GM, Al-Khalidi H, Gallup D, Dignacco P, Mussina K, et al. Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2019. p. E988–9.

Pokorney, Sean D., et al. “Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety.” CIRCULATION, vol. 140, no. 25, LIPPINCOTT WILLIAMS & WILKINS, 2019, pp. E988–89.

Pokorney SD, Chertow GM, Al-Khalidi H, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia D, Jones-Burton C, Lopes RD, Mahaffey KW, Middleton J, Mills D, Rymer JA, Thadhani R, Thomas KL, Winkelmayer WC, Granger CB. Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2019. p. E988–E989.